Albany, NY — (SBWIRE) — 05/06/2020 — Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030
DelveInsight launched a new report on Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030
Some of the key facts of the report
1. The total diagnosed Duchenne Muscular Dystrophy (DMD) prevalent population in the 7MM was 27,685 in 2017.2. The diagnosed DMD prevalent cases in the United States was 16,840 in 2017.3. The total diagnosed prevalent cases of DMD patients were found to be maximum in the age-group of 8–13 year and 14–19 year in the United States in 2017.
Key benefits of the report1. Duchenne Muscular Dystrophy market report covers a descriptive overview and comprehensive insight of the Duchenne Muscular Dystrophy epidemiology and Duchenne Muscular Dystrophy market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Duchenne Muscular Dystrophy market report provides insights into the current and emerging therapies.3. Duchenne Muscular Dystrophy market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Duchenne Muscular Dystrophy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Duchenne Muscular Dystrophy market.
Request for sample pages
“The Market Size of Duchenne Muscular Dystrophy in the 7MM was USD 266.06 Million in 2017.”
DMD treatments include the standard care along with the new therapeutic strategies that cover Genetic Therapies, Cell therapy utilizing muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and treatment of secondary cascades.
The medical management for Duchenne Muscular Dystrophy comprises several aspects such as Cardiac Care, Diet, Exercise, Respiratory Care, Braces, Spinal curvatures. The DMD treatment strategy also encompasses supportive treatment and psychosocial management.
Glucocorticoids, more precisely prednisone and Deflazacort, form the main drug for DMD treatment. Deflazacort is approved as Emflaza in the US. Corticosteroids stabilize muscle strength and function prolonging independent ambulation and delaying the progression of scoliosis and cardiomyopathy.
Deflazacort is an oxazoline derivate of prednisone. Deflazacort exhibits more bone-sparing and carbohydrate-sparing properties with less weight-gain effects and enhances strength and function. So, Deflazacort is the preferred choice over prednisone due to fewer side effects and the beneficial properties of muscle-sparing.
The launch of the emerging therapies is expected to significantly impact Duchenne Muscular Dystrophy treatment scenario in the upcoming years:-Drugs covered– Casimersen– SRP-9001– Puldysa (Idebenone)– Givinostat– Edasalonexent– Viltolarsen– PF-06939926– Vamorolone– TAS-205– Pamrevlumab (FG-3019)– Allogeneic Cardiosphere-Derived Cells (CAP-1002)– DS-5141bAnd many others
The key players in Duchenne Muscular Dystrophy market are:– Sarepta Therapeutics– Italfarmaco– Catabasis Pharmaceuticals– Nippon Shinyaku (NS Pharma)– Pfizer– Santhera Pharmaceuticals/ReveraGen BioPharma– Taiho Pharmaceutical– FibroGen– Capricor– Daiichi SankyoAnd many others
Table of contents1 Key Insights2 Duchenne Muscular Dystrophy Market Overview at a Glance3 DMD Disease Background and Overview4 Recognized Establishments5 Duchenne Muscular Dystrophy Epidemiology and Patient Population6 Country Wise-Epidemiology of DMD6.1 United States6.2 EU5 Countries6.3 Germany6.4 France6.5 Italy6.6 Spain6.7 United Kingdom6.8 Japan7 Duchenne Muscular Dystrophy Treatment8 General Guidelines on DMD9 United States Guidelines on Duchenne Muscular Dystrophy10 European Guidelines on Duchenne Muscular Dystrophy11 Unmet Needs12 DMD Marketed Drugs12.1 Vyondys 53 (Golodirsen): Sarepta Therapeutics12.2 Emflaza: PTC Therapeutics12.3 Exondys 51: Sarepta Therapeutics12.4 Translarna: PTC Therapeutics13 Duchenne Muscular Dystrophy Emerging Drugs13.1 Key Cross Competition13.2 Casimersen: Sarepta Therapeutics13.3 Puldysa (Idebenone): Santhera Pharmaceuticals13.4 Givinostat: Italfarmaco13.5 Edasalonexent: Catabasis Pharmaceuticals13.6 Viltolarsen: Nippon Shinyaku (NS Pharma)13.7 PF-06939926: Pfizer13.8 Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma13.9 TAS-205: Taiho Pharmaceutical13.10 Pamrevlumab (FG-3019): FibroGen13.11 SRP-9001: Sarepta Therapeutics13.12 Allogeneic Cardiosphere-Derived Cells (CAP-1002): Capricor13.13 DS-5141b: Daiichi Sankyo14 Duchenne Muscular Dystrophy 7 Major Market Analysis15 The United States Market Outlook16 EU-5 Countries: Market Outlook16.1 Germany16.2 France16.3 Italy16.4 Spain16.5 United Kingdom17 Japan: Market Outlook18 Case Reports19 Market Drivers20 Market Barriers21 SWOT Analysis for Duchenne Muscular Dystrophy22 Appendix23 DelveInsight Capabilities24 Disclaimer25 About DelveInsight
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/